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Eﬀ ect of fenoﬁ brate on amputation events in people with 
type 2 diabetes mellitus (FIELD study): a prespeciﬁ ed analysis 
of a randomised controlled trial
Kushwin Rajamani, Peter G Colman, Li Ping Li, James D Best, Merryn Voysey, Michael C D’Emden, Markku Laakso, John R Baker, Anthony C Keech, 
on behalf of the FIELD study investigators
Summary
Background Amputations in people with type 2 diabetes mellitus substantially impair their quality of life and impose 
high costs on health-care systems. Our aim was to assess the eﬀ ect of fenoﬁ brate on amputation events in a large 
cohort of patients with type 2 diabetes.
Methods In the Fenoﬁ brate Intervention and Event Lowering in Diabetes (FIELD) study, 9795 patients aged 
50–75 years with type 2 diabetes were randomly assigned by computer-generated randomisation sequence to receive 
fenoﬁ brate 200 mg per day (n=4895) or matching placebo (n=4900) for 5 years’ duration. Information about 
non-traumatic amputation—a prespeciﬁ ed tertiary endpoint of the study—was routinely gathered. Clinicians who 
were masked to treatment allocation adjudicated amputations as minor or major (below or above the ankle, 
respectively). Amputations were also classiﬁ ed on the basis of whether or not large-vessel disease was present in the 
limb, to distinguish those related to large-artery atherosclerosis from those predominantly related to microvascular 
disease. Analysis was by intention to treat (ITT). The FIELD study is registered as an International Standard 
Randomised Controlled Trial, number ISRCTN64783481.
Findings All 9795 patients were included in the ITT population. 115 patients had one or more non-traumatic 
lower-limb amputations due to diabetes. Previous cardiovascular disease, microvascular disease, previous 
non-traumatic amputation or skin ulcer, smoking, and longer duration of diabetes were more frequent in patients 
who had amputations during the trial than in those who had other cardiovascular events or in those who had neither 
event (all p<0·001 for three-way comparison). Mean lipid concentrations diﬀ ered between patients who had on-study 
amputations and those who had other cardiovascular events or neither event, but by no more than 0·2 mmol/L. The 
risks of ﬁ rst amputation (45 vs 70 events; hazard ratio [HR] 0·64, 95% CI 0·44–0·94; p=0·02) and minor amputation 
events without known large-vessel disease (18 vs 34 events; 0·53, 0·30–0·94; p=0·027) were lower for patients 
assigned to fenoﬁ brate than for patients assigned to placebo, with no diﬀ erence between groups in risk of major 
amputations (24 vs 26 events; 0·93, 0·53–1·62; p=0·79).
Interpretation Classic markers of macrovascular and microvascular risk were associated with lower extremity 
amputations in patients with type 2 diabetes. Treatment with fenoﬁ brate was associated with a lower risk of 
amputations, particularly minor amputations without known large-vessel disease, probably through non-lipid 
mechanisms. These ﬁ ndings could lead to a change in standard treatment for the prevention of diabetes-related 
lower-limb amputations.
Funding Laboratoires Fournier SA (now part of Solvay Pharmaceuticals) and National Health and Medical Research 
Council of Australia.
Introduction
Diabetes mellitus is the leading cause of non-traumatic 
lower-extremity amputations in the developed world.1 
In the USA in 2001, at least one amputation due to 
diabetes occurred every 2 h, with an annual cost 
exceeding US$1·6 billion.2,3 Despite rigorous man-
agement of reversible factors, probably around one in 
ten patients with diabetes will eventually need at least 
one amputation. Neither control of glycaemia or blood 
pressure nor lowering of cholesterol has prevented the 
risk of amputation, underscoring the importance of 
assessing the management of other potential risk 
factors. Any further therapeutic option to prevent the 
morbidity and mortality associated with amputation 
would be highly desirable.
The aim of the Fenoﬁ brate Intervention and Event 
Lowering in Diabetes (FIELD) study was to assess 
whether long-term lipid-lowering treatment with 
fenoﬁ brate could reduce adverse macrovascular and 
microvascular outcomes in patients with type 2 diabetes, 
including amputations.4 Previously, we found that 
fenoﬁ brate had a favourable eﬀ ect on microvascular 
disease in terms of the need for laser therapy for 
diabetic retinopathy,5 beyond what could be expected 
from a moderate observed reduction in blood pressure. 
The eﬀ ect of fenoﬁ brate treatment was independent of 
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haemoglobin A1c (HbA1c) and concomitant medications, 
and unlikely to be related to the drug’s lipid-lowering 
eﬀ ects.6 The study reported here analysed the eﬀ ect of 
fenoﬁ brate on lower-limb amputation events, and 
investigated the diﬀ erential eﬀ ects of this treatment on 
major and minor amputations with and without 
associated large-vessel disease.
Methods
Patients
The design and main results of the FIELD study, 
including safety proﬁ le, have been published elsewhere.4,5 
Brieﬂ y, patients aged 50–75 years were eligible for 
inclusion if they had a diagnosis of type 2 diabetes 
according to WHO criteria, an initial plasma total 
cholesterol concentration between 3·0 mmol/L and 
6·5 mmol/L plus a total cholesterol/HDL-cholesterol ratio 
of 4·0 or more, or a plasma triglyceride concentration 
between 1·0 mmol/L and 5·0 mmol/L, without needing 
lipid-modifying treatment at study entry. Individuals 
with renal impairment, chronic liver disease, 
symptomatic gallbladder disease, or those who had 
experienced a cardiovascular event within the 3 months 
before recruitment were excluded.
All patients provided written informed consent, and 
the study protocol was approved by local and national 
ethics committees in accordance with the Declaration of 
Helsinki and Good Clinical Practice guidelines.
Randomisation and masking
A central telephone computer randomisation service that 
used dynamic balancing7 to stratify patients according to 
important prognostic variables was used to randomly 
assign patients to intervention or control. All investigators 
and staﬀ , except the authorised study statistician, were 
masked to treatment allocation both before and after 
randomisation. The success of masking was not formally 
assessed.
Procedures
9795 patients were enrolled and randomly assigned to 
receive once-daily micronised fenoﬁ brate 200 mg 
(Laboratoires Fournier, Dijon, France; n=4895) or 
matching placebo (n=4900). Patients were followed up at 
4–6-month intervals for a median follow-up of 5 years, and 
all study outcomes and serious adverse events were 
recorded. Non-traumatic amputation was a prespeciﬁ ed 
tertiary endpoint. All non-traumatic amputations that 
occurred during study follow-up (on-study amputations) 
were reviewed separately by two clinicians who were 
masked to treatment allocation (KR, LPL), and any 
discrepancies were resolved by mutual agreement. All 
available baseline and on-study lower-limb angiograms 
and duplex ultrasounds of patients who had an amputation 
were reviewed for this analysis, but vascular status was 
not routinely measured at baseline in this study, or 
obtained thereafter for those who did not have an 
amputation. Major amputations were deﬁ ned as those 
above the ankle and minor amputations as those below 
the ankle.8 An additional classiﬁ cation based on the cause 
of amputation  was also devised. The ﬁ rst group consisted 
of amputations of digits and forefoot without previous or 
concurrent large-vessel disease (including angioplasty and 
bypass surgery) in the same limb or evidence of causative 
embolism; these amputations were classiﬁ ed as minor 
amputations without known large-vessel disease and were 
judged to be related to microvascular disease. The second 
group consisted of major amputations as well as minor 
amputations with documented large-vessel disease in the 
aﬀ ected limb or evidence of embolism. These amputations 
were judged to be related to atherosclerotic disease of the 
major peripheral arteries.
Statistical analysis
The study oﬀ ered 80% power to detect an observed 
22% reduction in cardiovascular events.4 All analyses 
Fenoﬁ brate (n=4895) Placebo (n=4900)
General characteristics
Male 3071 (63%) 3067 (63%)
Age at visit 1 (years) 62·2 (6·8) 62·2 (6·9)
Diabetes duration (years)* 5 (2–10) 5 (2–10)
Body-mass index (kg/m²) 29·8 (26·8–33·6) 29·8 (26·7–33·4)
Systolic blood pressure (mm Hg) 140 (15) 141 (15)
Diastolic blood pressure (mm Hg) 82 (9) 82 (9)
Current or ex-smoker 2916 (60%) 2950 (60%)
Clinical history
Previous non-traumatic amputation or diabetic skin ulcer 165 (3%) 151 (3%)
Previous cardiovascular disease 1068 (22%) 1063 (22%)
History of hypertension* 2776 (57%) 2768 (56%)
Neuropathy 707 (14%) 687 (14%)
Laboratory data†
Total cholesterol (mmol/L) 5·04 (0·69) 5·03 (0·71)
LDL cholesterol (mmol/L) 3·07 (0·64) 3·07 (0·66)
HDL cholesterol (mmol/L) 1·10 (0·26) 1·10 (0·26)
Triglycerides (mmol/L) 1·74 (1·34–2·34) 1·73 (1·34–2·30)
Plasma haemoglobin A1c (%) 7·08% (1·37) 7·05% (1·33)
Plasma creatinine (μmol/L) 77·7 (15·9) 77·4 (15·7)
Microalbuminuria or macroalbuminuria‡ 1268 (26%) 1247 (25%)
Baseline medication
Aspirin 1448 (30%) 1455 (30%)
Angiotensin-converting enzyme inhibitor 1716 (35%) 1725 (35%)
Angiotensin-II receptor antagonist 280 (6%) 265 (5%)
Metformin alone 828 (17%) 823 (17%)
Sulphonylurea alone 809 (17%) 799 (16%)
Metformin and sulphonylurea 1207 (25%) 1196 (24%)
Insulin alone or with oral agent 691 (14%) 688 (14%)
Data are number (%), mean (SD), or median (IQR). For further details see reference 5. *Reported at visit 1 (screening visit). 
†Mean of pre-randomisation visits for lipids, haemoglobin A1c, and creatinine. ‡Microalbuminuria deﬁ ned as urine albumin/
creatinine ratio ≥2·5 mg/mmoL and <25 mg/mmoL for men, and ≥3·5 mg/mmoL and <35 mg/mmoL for women; 
macroalbuminuria deﬁ ned as urine albumin/creatinine ratio ≥25 mg/mmoL for men and ≥35 mg/mmoL for women.
Table 1: Baseline characteristics and medication
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were done on an intention-to-treat basis. Baseline 
characteristics were analysed with χ² tests for categorical 
variables, t tests, or analysis of variance for continuous 
variables, or, if the distribution of the data was not 
normal, by Wilcoxon rank-sum tests (two-way analysis) 
or Kruskal-Wallis tests (three-way analysis). Proportional 
hazards regression was used to compute hazard ratios 
(HRs) and 95% CIs9,10 to assess the eﬀ ect of fenoﬁ brate 
treatment on the time to amputation (the proportional 
hazards assumption was assessed by use of the 
Harrell-Lee test11). Where appropriate, p values were 
computed with the log-rank test.10 Cumulative hazard 
curves of the time to the ﬁ rst amputation according to 
the amputation classiﬁ cation, and by treatment group, 
were calculated by use of the Kaplan-Meier method.10
For multiple event analysis, a Poisson model on the 
number of amputations was used and adjusted for 
months of observation and overdispersion,12 by use of the 
Pearson method.13 The Poisson analysis yielded an 
incidence rate ratio (analogous to the HR) that reﬂ ected 
the change in event rate per unit time for the fenoﬁ brate 
group relative to the placebo group. A basic risk model 
was developed to identify the most important predictors 
of amputations. Variables in the model were initially 
determined by use of backwards selection of all baseline 
characteristics in table 1 plus ﬁ brinogen and homocysteine 
in a proportional hazards model, and then conﬁ rmed by 
exhaustive search methods.14 The possibility of over-ﬁ tting 
because of the large number of potential predictors 
assessed and the small number of events was examined 
by calculating the heuristic shrinkage factor.11 The 
shrinkage factor of 0·9 indicates that the degree of 
over-ﬁ tting was negligible. Since only ﬁ ve patients, none 
of whom had undergone amputation, had any missing 
data, no statistical adjustment was made for this. All 
statistical inferences were drawn with a two-sided p value 
of 0·05. Results are presented unadjusted for multiple 
comparisons.15 SAS (version 9.1) and ACCORD (Analysis 
of Censored and Correlated Data; version 1.6.3, 2008) 
software was used for the analyses. This study is 
registered as an International Standard Randomised 
Controlled Trial, number ISRCTN64783481.
Role of the funding source
Two non-voting representatives of the main sponsor 
attended meetings of the management committee. The 
sponsors of the study had no role in data collection or 
data analysis. The authors had full access to all the data 
in the study. The authors and study management 
committee had ﬁ nal responsibility for the decision to 
submit the manuscript for publication.
Results
Figure 1 shows the trial proﬁ le, and table 1 the baseline 
characteristics of the study participants. 115 patients had 
lower-limb amputations due to diabetes, of whom 47 had 
more than one amputation  (ranging from two to six). All 
patients who reported a non-traumatic amputation were 
followed up until the completion of the study. Additionally, 
there were three cases of amputation (all in patients 
assigned to placebo) that were not related to diabetes 
(a ﬁ nger amputation secondary to known Raynaud’s 
disease, and two small-toe amputations secondary to claw 
toe deformity and not related to diabetic neuropathy); 
these cases were therefore excluded from any further 
analysis.
Baseline characteristics diﬀ ered between patients who 
had on-study amputations, those who had other 
cardiovascular events, and those who had neither event 
(table 2). Patients who had on-study amputations were 
more likely to be male, to be taller, or smoke, and had a 
longer median duration of diabetes than patients from 
the other two groups. They were also more likely to have 
reported previous cardiovascular disease (myocardial 
infarction, angina, coronary revascularisation, stroke, or 
peripheral vascular disease) or microvascular disease at 
baseline (including retinopathy, neuropathy, and 
nephropathy). Furthermore, occurrence of micro-
albuminuria and macroalbuminuria, and plasma HbA1c 
were all higher in patients who had amputations than in 
those who had other cardiovascular events or had 
neither event. Mean lipid concentrations diﬀ ered, but 
by no more than 0·2 mmol/L (table 2). Patients with 
amputations had more prescriptions at baseline of 
angiotensin-converting enzyme inhibitors, and a higher 
proportion used insulin than patients in the other two 
groups, reﬂ ecting their longer diabetes duration, worse 
glycaemic control, and higher occurrence of micro-
vascular and macrovascular complications.
12 lost to follow-up
  4 withdrew consent
10 lost to follow-up
   5 withdrew consent
4885 vital status conﬁrmed 
            at end of study
                  70 with amputation
            4815 no amputation*
4879 vital status conﬁrmed 
            at end of study
                  45 with amputation
            4834 no amputation 
4895 analysed in ITT 
            population
4900 analysed in ITT 
            population
1334 declined consent
2625 not eligible
   146 other reasons
4900 assigned to placebo4895 assigned to fenoﬁbrate
9795 randomised
13 900 patients screened 
Figure 1: Trial proﬁ le of amputation study
ITT=intention to treat. *Three patients had non-traumatic amputation unrelated to diabetes.
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Amputation due to diabetes during 
study follow-up* (n=115)
Other cardiovascular event 
(n=1251)
No amputation or cardiovascular 
event (n=8429)
p value†
Male 93 (81%) 944 (75%) 5101 (61%) <0·0001
Age at visit 1 (years) 65 (6) 64 (7) 62 (7) <0·0001
Diabetes duration (years) 9 (4–15) 7 (3–12) 5 (2–9) <0·0001
Body-mass index (kg/m²) 29·5 (26·6–33·4) 29·7 (26·8–33·1) 29·8 (26·8–33·6) 0·594
Height, men (cm) 176 (171–180) 174 (169–178) 175 (170–179) <0·0001
Height, women (cm) 165 (161–166) 161 (156–164) 161 (157–165) 0·011
Waist–hip ratio 0·96 (0·91–1·00) 0·95 (0·91–1·00) 0·93 (0·88–0·98) <0·0001
Systolic blood pressure (mm Hg) 144 (15) 144 (16) 140 (15) <0·0001
Diastolic blood pressure (mm Hg) 82 (8) 83 (9) 82 (8) 0·040
Current smoker 23 (20%) 152 (12%) 747 (9%) <0·0001‡
Ex-smoker 61 (53%) 688 (55%) 4195 (50%)
Clinical history
Previous non-traumatic amputation or diabetic skin ulcer 35 (30%) 46 (4%) 235 (3%) <0·0001
Previous cardiovascular disease§ 67 (58%) 512 (41%) 1552 (18%) <0·0001
Previous MI, angina, CABG, or PTCA 34 (30%) 383 (31%) 988 (12%) <0·0001
Previous stroke 12 (10%) 80 (6%) 255 (3%) <0·0001
Previous peripheral vascular disease 43 (37%) 167 (13%) 502 (6%) <0·0001
Microvascular disease 65 (57%) 380 (30%) 1580 (19%) <0·0001
Retinopathy 34 (30%) 162 (13%) 618 (7%) <0·0001
Neuropathy 57 (50%) 257 (21%) 1081 (13%) <0·0001
Nephropathy 8 (7%) 42 (3%) 229 (3%) 0·013
Laboratory data¶
Total cholesterol (mmol/L) 4·92 (0·64) 5·07 (0·69) 5·03 (0·71) 0·026
LDL cholesterol (mmol/L) 3·00 (0·68) 3·13 (0·63) 3·06 (0·65) 0·002
HDL cholesterol (mmol/L) 1·05 (0·27) 1·04 (0·24) 1·11 (0·26) <0·0001
Triglycerides (mmol/L) 1·77 (1·30–2·31) 1·82 (1·39–2·44) 1·72 (1·34–2·31) 0·0007
Plasma haemoglobin A1c (%) 7·5% (6·8–8·7) 7·1% (6·4–8·1) 6·8% (6·1–7·8) <0·0001
Plasma creatinine (μmol/L) 85 (18) 83 (17) 77 (15) <0·0001
Homocysteine (μmol/L) 11 (9–14) 10 (9–13) 9 (8–11) <0·0001
Dyslipidaemia|| 46 (40%) 537 (43%) 3127 (37%) 0·0003
Microalbuminuria** 46 (40%) 368 (29%) 1697 (20%) <0·0001
Macroalbuminuria†† 20 (17%) 97 (8%) 287 (3%) <0·0001
Baseline cardiovascular medication
Angiotensin-converting enzyme inhibitor 56 (49%) 476 (38%) 2749 (33%) <0·0001
Aspirin 43 (37%) 523 (42%) 2263 (27%) <0·0001
Angiotensin-II receptor agonist 3 (3%) 65 (5%) 454 (5%) 0·410
Baseline blood-glucose-lowering medication
Diet alone 8 (7%) 234 (19%) 2366 (28%) <0·0001
Metformin alone 10 (9%) 181 (14%) 1530 (18%) 0·0003
Sulphonylurea alone 12 (10%) 208 (17%) 1391 (17%) 0·215
Metformin and sulphonylurea 40 (35%) 362 (29%) 1918 (23%) <0·0001
Other oral agent alone 0 (0%) 2 (0·2%) 17 (0·2%) 0·850
Metformin or sulphonylurea or both and other agent 5 (4%) 27 (2%) 138 (2%) 0·041
Insulin alone 18 (16%) 106 (8%) 483 (6%) <0·0001
Insulin and oral agent 22 (19%) 131 (10%) 586 (7%) <0·0001
Data are number (%), mean (SD), or median (IQR). CABG=coronary artery bypass graft. MI=myocardial infarction. PTCA=percutaneous transluminal coronary angioplasty. *Patients who had both an amputation 
and another cardiovascular event were counted only in the amputations column. †p value for three-way comparison. p values are from χ² tests for categorical variables, ANOVA for normally distributed continuous 
variables with homogeneous variance, or Kruskal–Wallis test for non-normally distributed continuous variables or those with non-homogeneous variance. ‡p value from three-way χ² test of current smokers, 
ex-smokers, and non-smokers. §Previous cardiovascular disease comprises previous MI, angina, CABG, PTCA, stroke, peripheral vascular disease, and revascularisation. ¶Mean of pre-randomisation visits for lipids, 
haemoglobin A1c and creatinine. ||Men: HDL cholesterol concentration <1·03 mmol/L and triglyceride concentration ≥1·7 mmol/L; women: HDL cholesterol concentration <1·29 mmol/L and triglyceride 
concentration ≥1·7 mmol/L. **Microalbuminuria deﬁ ned as urine albumin/creatinine ratio ≥2·5 mg/mmoL and <25 mg/mmoL for men, and ≥3·5 mg/mmoL and <35 mg/mmoL for women. ††Macroalbuminuria 
deﬁ ned as urine albumin/creatinine ratio ≥25 mg/mmoL for men and ≥35 mg/mmoL for women. 
Table 2: Baseline characteristics by subsequent lower-limb amputation, other cardiovascular event, or neither
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Of the 115 patients who had an on-study lower-limb 
amputation due to diabetes, 65 patients had only minor 
amputations and 50 had major or both types of 
amputations. Patients with only minor amputations had 
a higher frequency of microvascular disease at baseline 
(42 [65%] patients vs 23 [46%] patients, p=0·046), in 
particular neuropathy (39 [60%] vs 18 [36%], p=0·011), 
than did those with major or both types of amputations. 
Patients with only minor amputations also had 
signiﬁ cantly lower mean systolic blood pressure 
(142 mm Hg [SD 12] vs 148 mm Hg [18], p=0·043), a lower 
occurrence of previous cardiovascular disease (31 [48%] 
vs 36 [72%], p=0·009), and higher mean concentration of 
plasma LDL cholesterol (3·1 mmol/L [0·6] vs 2·9 mmol/L 
[0·7], p=0·043) than did those with major or both types of 
amputations.
39 patients had only minor amputations without 
large-vessel disease in the aﬀ ected limb and the remaining 
76 had at least one major or minor amputation with 
large-vessel disease (table 3). Patients whose amputations 
were all minor without large-vessel disease were similar 
in most respects to others with amputations, except that 
they were a mean of 3 years younger, and had a higher 
body-mass index and a higher frequency of microvascular 
disease at baseline (in particular neuropathy). Analysis of 
the amputations according to the causative classiﬁ cation 
showed no signiﬁ cant diﬀ erence in baseline medication 
between groups.
Of the 115 patients who had one or more non-traumatic 
amputations due to diabetes, 45 had been allocated to 
fenoﬁ brate and 70 to placebo (ﬁ gure 2). The risk of a ﬁ rst 
non-traumatic amputation was lower in the fenoﬁ brate 
group than in the placebo group (HR 0·64, 95% CI 
0·44–0·94; p=0·02; ﬁ gure 2 and ﬁ gure 3). This ﬁ nding 
reﬂ ects the lower risks of minor amputations associated 
with fenoﬁ brate compared with placebo (HR 0·54, 
0·34–0·85; p=0·007). However, the risk of major 
amputations did not diﬀ er signiﬁ cantly between groups 
(HR 0·93, 0·53–1·62; p=0·79; ﬁ gure 2 and ﬁ gure 3).
Figure 2 shows that the risk of a ﬁ rst minor amputation 
without associated large-vessel disease was lower in the 
fenoﬁ brate group than in the placebo group; however, 
the risk of a ﬁ rst major or minor amputation with 
large-vessel disease did not diﬀ er between treatment 
groups. The decrease in ﬁ rst diabetes-related amputa-
tions seemed to emerge after only 1·5 years of 
fenoﬁ brate use, with continued divergence of the 
cumulative hazard curves over the mean 5-year 
follow-up period (ﬁ gure 3).
The eﬀ ect of fenoﬁ brate on a ﬁ rst amputation was 
similar in those taking and not taking an angiotensin-
converting enzyme inhibitor or angiotensin-receptor 
blocker at baseline (p=0·4 for heterogeneity of treatment 
eﬀ ect). Similarly, the eﬀ ect of fenoﬁ brate did not diﬀ er 
between those with good (HbA1c <7·0%) or poor 
(HbA1c ≥7·0%) glycaemic control (p=0·6 for heterogeneity 
of treatment eﬀ ect) or between those with or without 
Minor amputation 
without 
large-vessel 
disease (n=39)
Major or minor 
amputation with 
large-vessel 
disease (n=76)*
p value†
Male 30 (77%) 63 (83%) 0·441
Age at visit 1 (years) 63 (6) 66 (6) 0·019
Diabetes duration (years) 11 (7–22) 9 (4–15) 0·041
Body-mass index (kg/m²) 30·9 (28·7–36·4) 28·6 (25·8–32·0) 0·004
Waist–hip ratio 0·97 (0·90–1·00) 0·96 (0·91–1·00) 0·690
Height (cm) 174 (8) 173 (8) 0·278
Systolic blood pressure (mm Hg) 143 (12) 145 (16) 0·455
Diastolic blood pressure (mm Hg) 83 (7) 81 (9) 0·166
Current smoker 6 (15%) 17 (22%) 0·375‡
Ex-smoker 20 (51%) 41 (54%)
Clinical history
Previous amputation or diabetic skin ulcer 15 (38%) 20 (26%) 0·180
Previous cardiovascular disease§ 17 (44%) 50 (66%) 0·022
Previous MI, angina, CABG, or PTCA 8 (21%) 26 (34%) 0·128
Stroke 2 (5%) 10 (13%) 0·182
Peripheral vascular disease 11 (28%) 32 (42%) 0·145
Microvascular disease 29 (74%) 36 (47%) 0·006
Retinopathy 14 (36%) 20 (26%) 0·286
Neuropathy 26 (67%) 31 (41%) 0·009
Nephropathy 2 (5%) 6 (8%) 0·581
Laboratory data¶
Total cholesterol (mmol/L) 5·03 (0·66) 4·86 (0·63) 0·187
LDL cholesterol (mmol/L) 3·09 (0·67) 2·95 (0·68) 0·294
HDL cholesterol (mmol/L) 1·00 (0·25) 1·07 (0·27) 0·179
Triglycerides (mmol/L) 1·95 (1·39–2·49) 1·69 (1·28–2·23) 0·225
Plasma haemoglobin A1c (%) 8·1% (7·0–9·2) 7·4% (6·7–8·5) 0·087
Plasma creatinine (μmol/L) 84 (18) 86 (19) 0·640
Homocysteine (μmol/L) 10·8 (8·8–12·8) 11·6 (9·2–14·1) 0·266
Dyslipidaemia|| 18 (46%) 28 (37%) 0·335
Microalbuminuria** 14 (36%) 32 (42%) 0·520
Macroalbuminuria†† 10 (26%) 10 (13%) 0·095
Baseline blood-glucose-lowering medication
Diet alone 1 (3%) 7 (9%) 0·185
Metformin alone 3 (8%) 7 (9%) 0·784
Sulphonylurea alone 2 (5%) 10 (13%) 0·182
Metformin and sulphonylurea 18 (46%) 22 (29%) 0·067
Other oral agent alone 0 (0%) 0 (0%) ··
Metformin or sulphonylurea or both and other agent 3 (8%) 2 (3%) 0·208
Insulin alone 5 (13%) 13 (17%) 0·549
Insulin and oral agent 7 (18%) 15 (20%) 0·817
Data are number (%), mean (SD), or median (IQR). CABG=coronary artery bypass graft. MI=myocardial infarction. 
PTCA=percutaneous transluminal coronary angioplasty. *13 patients who had a minor amputation without large-vessel 
disease plus another type of amputation are included in this group. †p values are from χ² tests for categorical variables, 
t test for normally distributed continuous variables, or Wilcoxon rank-sum test for non-normally distributed continuous 
variables. ‡p value from three-way χ² test of current smokers, ex-smokers, and non-smokers. §Previous cardiovascular 
disease comprises previous MI, angina, CABG, PTCA, stroke, peripheral vascular disease, or revascularisation. 
¶Mean of pre-randomisation visits for lipids, haemoglobin A1c, and creatinine. ||Men: HDL cholesterol concentration 
<1·03 mmol/L and triglyceride concentration ≥1·7 mmol/L; women: HDL cholesterol concentration <1·29 mmol/L and 
triglyceride concentration  ≥1·7 mmol/L. **Microalbuminuria deﬁ ned as urine albumin/creatinine ratio ≥2·5 mg/mmoL 
and <25 mg/mmoL for men, and ≥3·5 mg/mmoL and <35 mg/mmoL for women. ††Macroalbuminuria deﬁ ned as 
urine albumin/creatinine ratio ≥25 mg/mmoL for men and ≥35 mg/mmoL for women.
Table 3: Baseline characteristics of patients who had a lower-limb amputation, by presence of large-vessel 
disease
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dyslipidaemia (ie, men: HDL cholesterol concentration 
less than 1·03 mmol/L and triglyceride concentration 
1·7 mmol/L or more; women: HDL cholesterol 
concentration less than 1·29 mmol/L and triglyceride 
concentration 1·7 mmol/L or more; p=0·5 for 
heterogeneity of treatment eﬀ ect).
Of the 190 non-traumatic diabetes-related amputations 
in total, 73 occurred in patients assigned to fenoﬁ brate 
and 117 in patients assigned to placebo. This result 
represents a further 28 amputations in 18 patients 
assigned to fenoﬁ brate compared with 47 further 
amputations in 29 patients assigned to placebo. When 
multiple amputations per patient were considered, the 
HR for the eﬀ ect of fenoﬁ brate treatment on the number 
of amputations was 0·63 (0·40–0·97; p=0·040; ﬁ gure 2).
The strongest predictors of a ﬁ rst on-study amputation 
in a multivariable model were a history of previous 
non-traumatic amputation or diabetic skin ulcer, 
neuropathy, or previous peripheral vascular disease. HRs 
were 5·6 (3·6–8·6) for previous amputation or skin ulcer, 
2·7 (1·8–4·0) for neuropathy, and 2·5 (1·7–3·9) for 
peripheral vascular disease (all p<0·0001). Non-modiﬁ able 
factors of height and age were also predictive: the HR for 
height (per 10 cm) was 1·6 (1·3–2·0) and for age (per 
each 5 additional years) was 1·3 (1·2–1·5; also both 
p<0·0001). Other predictors included current smoking, 
albuminuria, HbA1c (per 1% higher level), retinopathy, 
and percutaneous transluminal coronary angioplasty 
(data not shown). None of the lipid variables (total and 
HDL cholesterol concentrations, triglycerides) were 
signiﬁ cantly associated with amputation in multivariable 
analysis and therefore none remained in the ﬁ nal model. 
Adjusted for these signiﬁ cant risk factors, the HR for the 
eﬀ ect of fenoﬁ brate treatment on risk of a ﬁ rst 
diabetes-related amputation was 0·63 (0·43–0·92; 
p=0·016). This ﬁ nding represents an absolute risk 
reduction of about 0·5% (95% CI 0·1–0·9). Serious 
adverse events associated with fenoﬁ brate treatment have 
been reported elsewhere.5
Discussion
This study showed that amputation risk in patients with 
type 2 diabetes was lower in patients assigned to 
treatment with long-term fenoﬁ brate than in those 
assigned to placebo. The cumulative hazard curves 
showed a reduction in amputation rates that seemed to 
emerge after just 1·5 years of fenoﬁ brate use. The 
reduction in the risk of minor amputation where there 
was no known large-vessel disease was most striking, by 
contrast with a non-signiﬁ cant reduction for major or 
large-vessel amputations. This analysis substantiates the 
established macrovascular5 and microvascular 
(albuminuria5 and retinopathy6) beneﬁ ts of fenoﬁ brate 
use, which should also be considered in calculating the 
economic beneﬁ ts of such treatment.
The number of patients needed to treat (NNT) with 
fenoﬁ brate over 5 years to prevent at least one amputation 
in one patient is 197, but is 25 for someone with previous 
foot ulcer and albuminuria. These results compare with 
NNTs with fenoﬁ brate of 17 and 90 to prevent laser 
treatment for retinopathy in patients with and without a 
history of retinopathy, respectively,6 68 to prevent 
progression of albuminuria,5 and 71 and 23 to prevent 
one or more cardiovascular events overall and in those 
with marked dyslipidaemia, respectively.16
These eﬀ ects on amputation occurred in patients on 
optimum medical treatment (by current practice 
standards) to control risk factors that altered the 
progression of their diabetes. HbA1c did not change 
substantially from baseline in either treatment group over 
the 5-year study period (data not shown). Most importantly, 
the treatment eﬀ ects of fenoﬁ brate were irrespective of 
the level of glycaemic control and background use or 
not of angiotensin-converting enzyme inhibitors or 
angiotensin-receptor blockers, strongly suggesting that 
the drug’s eﬀ ects are additive to other measures. In the 
UK Prospective Diabetes Study,17 a reduction in HbA1c of 
0·9% over 10 years in patients treated with intensive 
blood glucose control compared with control patients did 
not result in signiﬁ cant changes in either amputation rate 
or death from peripheral vascular disease. Similarly, 
peripheral vascular disease was not signiﬁ cantly reduced 
by intensive glucose control in patients from the same 
study who were followed up for up to 20 years,18 or in 
patients from the ADVANCE study19 (the ACCORD study20 
has not published on amputations to date). Neither the 
HOPE study,21 which assessed the angiotensin-converting 
enzyme inhibitor, ramipril, nor the ADVANCE study,22 
which tested intensive blood pressure reduction with 
perindopril and indapamide, has reported any amputation 
data so far.
The most common pattern of dyslipidaemia in people 
with diabetes is hypertriglyceridaemia with or without 
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Figure 2: Eﬀ ects of fenoﬁ brate on ﬁ rst and all amputation events
HR=hazard ratio. Counts for each category of amputation are shown. *Patients were counted only once within 
each category but may be included in more than one category if they had more than one type of amputation. If a 
patient had more than one type of amputation, or more than one of the same type of amputation, only the ﬁ rst 
event of each type was analysed. †For all events, all amputations for each category are counted (Poisson method): 
the incidence rate ratio, analogous to the hazard ratio, is plotted.
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reduced HDL cholesterol concentrations. However, the 
eﬀ ects of treatment with fenoﬁ brate on the risk of 
amputation might go beyond the improvements in 
controlling the lipid proﬁ le, since no lipid variables were 
associated with the risk of amputation in multivariable 
analyses. Additionally, the Heart Protection Study,23 
which randomly assigned 5963 people with diabetes to 
either simvastatin or placebo, showed no diﬀ erence in 
amputation rates between groups, despite substantial 
reductions in total cholesterol and LDL cholesterol 
concentrations and modest changes in triglyceride and 
HDL cholesterol concentrations in the intervention 
group compared with controls. This ﬁ nding suggests 
that the eﬀ ects of fenoﬁ brate in reducing amputation 
risk are more likely to be non-lipid-mediated and, as 
such, unaﬀ ected by the diﬀ erent rates of statin use 
between treatment groups in the FIELD study.
Several theoretical mechanisms for the microvascular 
beneﬁ ts of fenoﬁ brate have been proposed. In a 
randomised placebo-controlled trial, treatment with 
fenoﬁ brate was associated with improved endothelial-
dependent vascular reactivity over 12 weeks,24 with 
reductions in markers of endothelial dysfunction and 
pro-inﬂ ammatory markers, including tumour necrosis 
factor α, interleukin 6, and interleukin 1β in plasma; 
another trial also showed that fenoﬁ brate treatment was 
associated with reduced viscosity.25 These results need to 
be substantiated by longer-term studies. In patients with 
hypertriglyceridaemia or metabolic syndrome, fenoﬁ brate 
improved ﬂ ow-mediated dilator response to hyperaemia, 
with increased adiponectin concentrations and improved 
insulin sensitivity.26 The drug might exert its 
antiangiogenic eﬀ ects directly,27 or by reducing tissue 
ischaemia through these actions.24–26 Fenoﬁ brate also 
activates AMP kinase in endothelial cells via a 
peroxisome-proliferating receptor-α independent path-
way, preventing retinal cell apoptosis,28 and possibly 
increasing nitric oxide synthesis.29 Fenoﬁ brate could also 
be protective through the inhibition of oxidative stress30 
(current FIELD studies of blood markers of inﬂ ammation 
and oxidation will help to investigate this mechanism 
further) and has been reported to have neuroprotective 
eﬀ ects in rodents,31 which could be particularly important 
in view of the key role of neuropathy in risk of 
amputation.
An amputation due to diabetes occurs around every 
30 s somewhere in the world.32 Amputations substantially 
impair quality of life33 and impose a major burden on 
health-care systems, with annual costs in the UK estimated 
at about £252 million34 and in the USA at about 
US$1648 million.3 Most of this expenditure is related to 
type 2 diabetes, with less than 10% accounted for by 
type 1 diabetes. Indirect costs would further increase these 
ﬁ gures substantially. 
Foot ulcers and infections are also a major source of 
morbidity, associated with neuropathy, abnormal foot 
biomechanics, peripheral arterial disease, and poor wound 
healing.35 Peripheral sensory neuropathy results in major 
or repeated minor trauma to the foot (often unnoticed), 
abnormal weight bearing, and subsequent callus formation 
and ulceration. Motor and sensory neuropathy leads to 
abnormal foot muscle mechanics and structural changes 
in the foot. Autonomic neuropathy results in anhidrosis 
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Figure 3: Cumulative risk curves of time to ﬁ rst amputation (minor, major, any) event, by treatment group
Patients could be counted in more than one category, but only once per category. 
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and altered superﬁ cial blood ﬂ ow that promotes drying of 
the skin and ﬁ ssure formation. Peripheral arterial disease 
and poor wound healing impede the resolution of minor 
skin breaks, allowing them to enlarge and become 
infected.35
Prevention is, therefore, the most essential strategy for 
avoiding diabetic foot ulcers and amputations; this 
approach involves identifying patients at high risk, 
providing education about appropriate foot care, and 
implementing measures to prevent ulceration (such as 
protective footwear and podiatry). Such foot care has 
reduced amputation risk by 45%.36 Our study lends support 
to the following predictors of future lower-limb amputation 
that were previously suggested in a smaller cohort study of 
1300 patients with a diﬀ erent study design:37 a history of 
previous foot ulcer, longer diabetes duration, presence of 
neuropathy or peripheral arterial disease, and poor 
glycaemic control.
Our study also identiﬁ ed height as a major predictor of 
amputations, with a 1·6-fold increase in risk for every 
10 cm increase in height, which is similar to a previous 
observational report of an odds ratio of 1·8 for each 10 cm 
increase in height.38 Two previous studies have described, 
in a mixed cohort of patients with and without diabetes, 
that hypercholesterolaemia and hypertension result in 
worse peripheral arterial disease outcomes.39,40 Although in 
our study these conditions were not independent predictors 
of amputation risk exclusively, they contributed towards 
amputation risk indirectly, since peripheral vascular 
disease was found to be an independent major risk factor.
There are limitations to this study, including the fact that 
there was no standardised routine testing (for example, 
angiography or ankle-brachial index) at baseline to assess 
vascular status, because it was not required by the study 
protocol. It is therefore possible that some amputations 
could have been misclassiﬁ ed by the failure to detect 
large-vessel disease, because of either unreported 
angiograms, or vascular studies or comorbidities that could 
have precluded revascularisation. However, if such 
non-diﬀ erential misclassiﬁ cation bias resulting from 
missed large-vessel disease had occurred, then the observed 
reduction with fenoﬁ brate in those with minor amputa-
tion without large-vessel disease would likely be an 
underestimate of the true treatment eﬀ ect in that group 
(because there was less eﬀ ect seen in those with large-vessel 
disease).
FIELD is the largest randomised controlled trial of 
type 2 diabetes mellitus reporting data for amputations, 
with a very large set of baseline variables. The risks of 
overall amputation were substantially lower in the 
fenoﬁ brate group than in the placebo group over 5 years, 
and the drug had a satisfactory safety proﬁ le (reported 
elsewhere).5 The proposed microvascular beneﬁ ts of such 
treatment are suggested by the signiﬁ cant risk reduction 
for minor amputations without large-vessel disease. 
These beneﬁ ts seem additive to any beneﬁ ts arising from 
good glycaemic control and the use of angiotensin-
converting enzyme inhibitors or angiotensin-receptor 
blockers, and therefore represent an important break-
through in the prevention of diabetic complications. 
These ﬁ ndings support the use of fenoﬁ brate, irrespective 
of the presence of dyslipidaemia, for the treatment of 
patients with type 2 diabetes who are at high risk for 
amputation (including those with peripheral vascular 
disease, existing microvascular complications, and a long 
duration of diabetes). This approach could help to reduce 
the substantial morbidity, mortality, and economic 
burden associated with amputation due to diabetes.
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